The impact of BDNF on the cognitive functions of ultra-high risk patients: An exploratory study

Affiliations

• ¹ Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France; AP-HP, GHU AP-HP Nord, DMU ESPRIT, service de Psychiatrie et Addictologie, Hôpital Louis Mourier, Colombes, France.
• ² Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France; GHU Paris Psychiatrie et Neurosciences, F-75674 Paris, France; Department of Psychiatry, McGill University, Montréal, QC H3A 0G4, Canada. Electronic address: boris.chaumette@inserm.fr.
• ³ Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France; GHU Paris Psychiatrie et Neurosciences, F-75674 Paris, France.
• ⁴ Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France.
• ⁵ Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France; MOODS Team, INSERM, CESP, Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, F-94275, France.